Major adverse kidney events
Disease2 papers2 findings
- Humans2
Associations
2SGLT2 inhibitors
downin humans1
1 study
SGLT2 inhibitors
downin humans1
SGLT2 inhibitors lower the risk of major adverse kidney events in humans (6.2 vs. 11.7%; hazard ratio 0.47).
Humansin T2DM patients undergoing TEER1 year
Outcomes of SGLT2 inhibitors after transcatheter mitral valve repair in patients with type 2 diabetes mellitus · Journal of cardiovascular medicine (Hagerstown, Md.) · 27 Aug 2026
GLP-1 receptor agonists
downin humans1HR 0.63
1 study
GLP-1 receptor agonists
downin humans1HR 0.63
GLP-1 receptor agonists lower the risk of major adverse kidney events in humans (HR, 0.63; 95% CI, 0.48-0.81).
Humansversus DPP-4i in men with prostate cancer undergoing ADT and T2Dmalesn = 659
Glucagon-like peptide-1 receptor agonist versus other anti-diabetic agents on patients with prostate cancer undergoing androgen-deprivation therapy · Frontiers in urology · 7 Aug 2026
Latest
9GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Adding a GLP-1 receptor agonist was linked to lower rates of major adverse kidney events (HR 0.70) compared with SGLT2 inhibitor monotherapy over 12…Adding a GLP-1 receptor agonist was linked to lower rates of major adverse kidney events (HR 0.70) compared with SGLT2 inhibitor monotherapy over 12 months.